Cyrus Harmon Sells 3,489 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon sold 3,489 shares of the firm’s stock in a transaction dated Wednesday, January 14th. The stock was sold at an average price of $29.12, for a total value of $101,599.68. Following the completion of the sale, the director directly owned 737,770 shares in the company, valued at $21,483,862.40. The trade was a 0.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Cyrus Harmon also recently made the following trade(s):

• On Tuesday, January 20th, Cyrus Harmon sold 10,000 shares of Olema Pharmaceuticals stock. The stock was sold at an average price of $26.88, for a total value of $268,800.00.
• On Monday, December 22nd, Cyrus Harmon sold 2,881 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $28.53, for a total value of $82,194.93.

Olema Pharmaceuticals Price Performance

Shares of Olema Pharmaceuticals stock opened at $26.29 on Thursday. The business has a 50 day moving average of $26.18 and a 200 day moving average of $13.80. Olema Pharmaceuticals, Inc. has a 52 week low of $2.86 and a 52 week high of $36.26. The company has a market cap of $1.81 billion, a PE ratio of -14.06 and a beta of 1.92. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). As a group, equities research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

Analysts Set New Price Targets

OLMA has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Wednesday, October 8th. Guggenheim initiated coverage on Olema Pharmaceuticals in a report on Wednesday, October 8th. They issued a “buy” rating and a $20.00 price objective for the company. Piper Sandler started coverage on Olema Pharmaceuticals in a research report on Wednesday, January 7th. They set an “overweight” rating and a $40.00 price objective for the company. Citigroup upped their target price on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Finally, JPMorgan Chase & Co. increased their price target on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Olema Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $41.00.

Hedge Funds Weigh In On Olema Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC grew its position in Olema Pharmaceuticals by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock valued at $94,000 after purchasing an additional 477 shares during the last quarter. Russell Investments Group Ltd. bought a new position in shares of Olema Pharmaceuticals in the third quarter worth approximately $53,000. Ameritas Investment Partners Inc. grew its holdings in shares of Olema Pharmaceuticals by 55.4% during the second quarter. Ameritas Investment Partners Inc. now owns 6,080 shares of the company’s stock valued at $26,000 after buying an additional 2,168 shares during the last quarter. Farther Finance Advisors LLC increased its position in shares of Olema Pharmaceuticals by 602.9% during the second quarter. Farther Finance Advisors LLC now owns 6,839 shares of the company’s stock valued at $29,000 after acquiring an additional 5,866 shares in the last quarter. Finally, FNY Investment Advisers LLC raised its holdings in Olema Pharmaceuticals by 100.0% in the 2nd quarter. FNY Investment Advisers LLC now owns 10,000 shares of the company’s stock worth $42,000 after acquiring an additional 5,000 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.